Sign In
Buy INCY
$119.80
-0.800 (-0.663%)
At Close: Aug 05, 2026
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Positive CHMP opinion for Pemigatinib for Previously Treated, Unresectable Locally Advanced or Metastatic CCA with FGFR2 fusion or rearrangement
Incyte's (INCY) BLA for Cancer Drug Accepted for Priority Review
03:03pm, Friday, 22'nd Jan 2021
Incyte's (INCY) application for pipeline candidate, retifanlimab, for adult patients with locally advanced or metastatic squamous cell carcinoma of the anal canal (SCAC) gets Priority Review.
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Announces Acceptance and Priority Review of BLA for Retifanlimab as a Potential Treatment for Squamous Cell Carcinoma of the Anal Canal (SCAC)
Incyte to Report Fourth Quarter and Year-End 2020 Financial Results
08:00am, Tuesday, 19'th Jan 2021
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) announced today that it has scheduled its fourth quarter and year-end 2020 financial results conference call and webcast for 8:00 a.m. ET on Tue
MorphoSys and Incyte Announce Acceptance by Health Canada of the New Drug Submission for Tafasitamab
04:30pm, Tuesday, 12'th Jan 2021
PLANEGG/MUNICH, GERMANY and MONTREAL, QC / ACCESSWIRE / January 12, 2021 / MorphoSys AG (FSE:MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ:MOR) and Incyte (NASDAQ:INCY) today announced that Healt
Incyte (INCY) Partners With Cellenkos for Myelofibrosis Treatment
09:47am, Thursday, 31'st Dec 2020
Incyte (INCY) enters into a collaboration with Cellenkos to evaluate the combination of Jakafi and CK0804 in patients with myelofibrosis.
Why These Health Care Stocks Are Moving Today
02:03pm, Wednesday, 30'th Dec 2020
Altimmune (NASDAQ: ALT) shares were trading higher Wednesday after the company announced it began a multinational Phase 2 clinical trial of HepTcellTM for the treatment of chronic Hepatitis B. Altimm
Incyte and Cellenkos Enter into Global Development Collaboration Agreement for CK0804
07:30am, Wednesday, 30'th Dec 2020
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte and Cellenkos Enter into Global Development Collaboration Agreement for CK0804
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Announces Results of Phase 3 RUXCOVID Study of Ruxolitinib (Jakafi®) as a Treatment for Patients with COVID-19 Associated Cytokine Storm
INDIANAPOLIS, Dec. 11, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) announced today that The New England Journal of Medicine has published peer-reviewed results fro
Incyte to Present at Upcoming Investor Conference
08:00am, Wednesday, 09'th Dec 2020
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) announced today that it will present at the 39th Annual J. P. Morgan Virtual Healthcare Conference on Monday, January 11, 2021 at 7:30 a.m. EST.
WILMINGTON, Del. & PLANEGG/MUNICH, Germany--(BUSINESS WIRE)---- $INCY #ASH20--Data Evaluating Tafasitamab with and without Lenalidomide in Combination with R-CHOP in Patients with DLBCL Presented at A
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #ASH20--First Data from REACH3 Show Ruxolitinib (Jakafi) Significantly Improved Outcomes in Patients with Steroid-Refractory or Steroid-Dependent cGVHD
Incyte: Wait No More - Time To Buy
09:15am, Wednesday, 02'nd Dec 2020
Back on Dec. 29, 2019, I published an article here on Seeking Alpha, "Incyte Corporation: Wait And Watch." Those who waited and watched would have been well rewarded, with significantly lower share pr
Baricitinib Receives Emergency Use Authorization from the FDA for the Treatment of Hospitalized Patients with COVID-19
05:20pm, Thursday, 19'th Nov 2020
INDIANAPOLIS, Nov. 19, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) announced today that the U.S. Food and Drug Administration (FDA) issued an Emergency Use Authori
